ISIN | LU1540961759 |
---|---|
Valor Number | 35003342 |
Bloomberg Global ID | |
Fund Name | HBM Global Biotechnology Fund A USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 463.01 USD | 21.11.2024 |
---|---|---|
Previous Price * | 460.62 USD | 20.11.2024 |
52 Week High * | 509.65 USD | 08.11.2024 |
52 Week Low * | 365.87 USD | 28.11.2023 |
NAV * | 463.01 USD | 21.11.2024 |
Issue Price * | 463.01 USD | 21.11.2024 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 22,090,108 | |
Unit/Share Assets *** | 3,543,637 | |
Trading Information SIX |
YTD Performance | +3.28% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
---|---|---|
YTD Performance (in CHF) | +8.83% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
1 month | -5.50% |
21.10.2024 - 21.11.2024
21.10.2024 21.11.2024 |
3 months | -7.40% |
21.08.2024 - 21.11.2024
21.08.2024 21.11.2024 |
6 months | +6.25% |
21.05.2024 - 21.11.2024
21.05.2024 21.11.2024 |
1 year | +26.49% |
21.11.2023 - 21.11.2024
21.11.2023 21.11.2024 |
2 years | +15.41% |
23.11.2022 - 21.11.2024
23.11.2022 21.11.2024 |
3 years | +0.62% |
24.11.2021 - 21.11.2024
24.11.2021 21.11.2024 |
5 years | +19.51% |
27.11.2019 - 21.11.2024
27.11.2019 21.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 6.12% | |
---|---|---|
Amgen Inc | 6.08% | |
Gilead Sciences Inc | 4.75% | |
Zealand Pharma AS | 4.58% | |
Vertex Pharmaceuticals Inc | 4.39% | |
Regeneron Pharmaceuticals Inc | 3.97% | |
Biohaven Ltd | 3.77% | |
Alnylam Pharmaceuticals Inc | 3.63% | |
UCB SA | 3.40% | |
AstraZeneca PLC ADR | 2.94% | |
Last data update | 30.09.2024 |
TER | 0.0238% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 2.04% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |